• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Swedish Orphan Biovitrum Ab (OP: BIOVF )

    31.28 +0.73 (+2.39%)
    Streaming Delayed Price Updated: 11:57 AM EDT, Aug 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Swedish Orphan Biovitrum Ab

    Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
    Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
    Via Benzinga
    Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
    As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:  
    Via Benzinga
    Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
    The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t 
    Via Benzinga
    Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
    Via Benzinga
    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
    Investors are on the hunt for undervalued, underfollowed and emerging stocks and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. 
    Via Benzinga
    Sanofi's Hemophilia Candidate Goes Under Priority FDA Review
    Via Benzinga
    ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
    Via Benzinga
    Why Shares of CTI BioPharma Are Soaring Wednesday
    A buyout offer from Swedish Orphan Biovitrum drove up the stock's price. 
    Via The Motley Fool
    European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
    Swedish Orphan Biovitrum AB (OTC: BIOVF) has agreed to acquire CTI BioPharma (NASDAQ: CTIC) for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of  
    Via Benzinga
    Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year
    Via Benzinga
    Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
    Veru Inc. 
    Via Benzinga
    Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
    Via Benzinga
    The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis
    Via Benzinga
    The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
    Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... 
    Via Benzinga
    Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
    The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan... 
    Via Benzinga
    AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
    AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... 
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.